April 12, 2023
On May 30, 2023, the Texas Health and Human Services Commission (HHSC) will update the clinical prior authorization criteria for Livmarli to allow coverage for pediatric patients three months of age or older.
Livmarli is currently approved for pediatric patients one year of age or older and is included as part of the cholestatic pruritis prior authorization.
The cholestatic pruritis prior authorization is optional for managed care organizations.